{"id":"https://openalex.org/W2169715407","doi":"https://doi.org/10.1592/phco.27.8.1102","title":"Loss of Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Were Receiving Initial Metformin, Sulfonylurea, or Thiazolidinedione Monotherapy","display_name":"Loss of Glycemic Control in Patients with Type 2 Diabetes Mellitus Who Were Receiving Initial Metformin, Sulfonylurea, or Thiazolidinedione Monotherapy","alternate_titles":[],"publication_year":2007,"publication_date":"2007-08-01","ids":{"openalex":"https://openalex.org/W2169715407","doi":"https://doi.org/10.1592/phco.27.8.1102","mag":"2169715407","pmid":"https://pubmed.ncbi.nlm.nih.gov/17655510"},"language":"en","primary_location":{"id":"doi:10.1592/phco.27.8.1102","doi":"https://doi.org/10.1592/phco.27.8.1102","is_oa":false,"landing_page_url":"https://doi.org/10.1592/phco.27.8.1102","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W2169715407"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5059950483","display_name":"Aylin Altan Riedel","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Aylin A. Riedel","raw_affiliation_strings":["Department of Health Economics and Outcomes, i3 Innovus, an Ingenix Company, Eden Prairie, Minnesota, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Economics and Outcomes, i3 Innovus, an Ingenix Company, Eden Prairie, Minnesota, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5059547603","display_name":"Herbert C. Heien","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Herbert Heien","raw_affiliation_strings":["Department of Health Economics and Outcomes, i3 Innovus, an Ingenix Company, Eden Prairie, Minnesota"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Health Economics and Outcomes, i3 Innovus, an Ingenix Company, Eden Prairie, Minnesota","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5028035210","display_name":"Jenifer Wogen","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210166701","display_name":"Medidata (United States)","ror":"https://ror.org/05y7kyx32","country_code":"US","type":"company","lineage":["https://openalex.org/I4210166701","https://openalex.org/I47431100"]}],"countries":["US"],"is_corresponding":true,"contributor_roles":[],"raw_author_name":"Jenifer Wogen","raw_affiliation_strings":["MedMentis Consulting LLC, Towaco, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"MedMentis Consulting LLC, Towaco, New Jersey","institution_ids":["https://openalex.org/I4210166701"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5077580297","display_name":"Craig A. Plauschinat","orcid":"https://orcid.org/0000-0002-8002-6838","observed_orcids":["https://orcid.org/0000-0002-8002-6838"]},"institutions":[{"id":"https://openalex.org/I4210117619","display_name":"Novartis (United States)","ror":"https://ror.org/028fhxy95","country_code":"US","type":"company","lineage":["https://openalex.org/I1283582996","https://openalex.org/I4210117619"]}],"countries":["US"],"is_corresponding":false,"contributor_roles":[],"raw_author_name":"Craig A. Plauschinat","raw_affiliation_strings":["Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey","institution_ids":["https://openalex.org/I4210117619"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":["https://openalex.org/A5028035210"],"corresponding_institution_ids":["https://openalex.org/I4210166701"],"apc_list":{"value":4030,"currency":"USD","value_usd":4030},"apc_paid":null,"fwci":2.9897,"has_fulltext":false,"cited_by_count":81,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.90586347,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":92,"max":99},"biblio":{"volume":"27","issue":"8","first_page":"1102","last_page":"1110"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10401","display_name":"Diabetes Treatment and Management","score":0.9961000084877014,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10560","display_name":"Diabetes Management and Research","score":0.0019000000320374966,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10027","display_name":"Diabetes, Cardiovascular Risks, and Lipoproteins","score":0.0006000000284984708,"subfield":{"id":"https://openalex.org/subfields/2712","display_name":"Endocrinology, Diabetes and Metabolism"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/type-2-diabetes","display_name":"type 2 diabetes","score":0.996999979019165},{"id":"https://openalex.org/keywords/glycemic-control","display_name":"glycemic control","score":0.796999990940094},{"id":"https://openalex.org/keywords/hba1c","display_name":"HbA1c","score":0.9169999957084656},{"id":"https://openalex.org/keywords/metformin","display_name":"metformin","score":0.8119999766349792},{"id":"https://openalex.org/keywords/sulfonylureas","display_name":"sulfonylureas","score":0.8999999761581421},{"id":"https://openalex.org/keywords/thiazolidinediones","display_name":"thiazolidinediones","score":1.0},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.8939999938011169},{"id":"https://openalex.org/keywords/secondary-treatment-failure","display_name":"secondary treatment failure","score":0.699999988079071},{"id":"https://openalex.org/keywords/antidiabetic-drugs","display_name":"antidiabetic drugs","score":0.7229999899864197},{"id":"https://openalex.org/keywords/cost-effectiveness","display_name":"cost-effectiveness","score":0.3400000035762787}],"concepts":[{"id":"https://openalex.org/C2776923340","wikidata":"https://www.wikidata.org/wiki/Q1393556","display_name":"Thiazolidinedione","level":4,"score":0.8754175305366516},{"id":"https://openalex.org/C2778854520","wikidata":"https://www.wikidata.org/wiki/Q418776","display_name":"Sulfonylurea","level":3,"score":0.8734716176986694},{"id":"https://openalex.org/C2780323712","wikidata":"https://www.wikidata.org/wiki/Q19484","display_name":"Metformin","level":3,"score":0.8521724939346313},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8370953798294067},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.6839338541030884},{"id":"https://openalex.org/C2780473172","wikidata":"https://www.wikidata.org/wiki/Q5572518","display_name":"Glycemic","level":3,"score":0.6585152745246887},{"id":"https://openalex.org/C555293320","wikidata":"https://www.wikidata.org/wiki/Q12206","display_name":"Diabetes mellitus","level":2,"score":0.520932137966156},{"id":"https://openalex.org/C2776999253","wikidata":"https://www.wikidata.org/wiki/Q1304270","display_name":"Combination therapy","level":2,"score":0.45767661929130554},{"id":"https://openalex.org/C167135981","wikidata":"https://www.wikidata.org/wiki/Q2146302","display_name":"Retrospective cohort study","level":2,"score":0.44956135749816895},{"id":"https://openalex.org/C2777180221","wikidata":"https://www.wikidata.org/wiki/Q3025883","display_name":"Type 2 diabetes","level":3,"score":0.41822415590286255},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.25804489850997925},{"id":"https://openalex.org/C2779306644","wikidata":"https://www.wikidata.org/wiki/Q2002370","display_name":"Insulin","level":2,"score":0.13938060402870178}],"mesh":[{"descriptor_ui":"D000284","descriptor_name":"Administration, Oral","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D003924","descriptor_name":"Diabetes Mellitus, Type 2","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006442","descriptor_name":"Glycated Hemoglobin","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":true},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007004","descriptor_name":"Hypoglycemic Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008137","descriptor_name":"Longitudinal Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008687","descriptor_name":"Metformin","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012189","descriptor_name":"Retrospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013453","descriptor_name":"Sulfonylurea Compounds","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017211","descriptor_name":"Treatment Failure","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D045162","descriptor_name":"Thiazolidinediones","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true}],"locations_count":2,"locations":[{"id":"doi:10.1592/phco.27.8.1102","doi":"https://doi.org/10.1592/phco.27.8.1102","is_oa":false,"landing_page_url":"https://doi.org/10.1592/phco.27.8.1102","pdf_url":null,"source":{"id":"https://openalex.org/S122731057","display_name":"Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy","issn_l":"0277-0008","issn":["0277-0008","1875-9114"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-100","russia-white-list-1"],"host_organization":"https://openalex.org/P4310320595","host_organization_name":"Wiley","host_organization_lineage":["https://openalex.org/P4310320595"],"host_organization_lineage_names":["Wiley"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy","raw_type":"journal-article"},{"id":"pmid:17655510","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/17655510","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Pharmacotherapy","raw_type":"Comparative Study"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Observational Study","id":"https://openalex.org/study-designs/observational-study"}],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":26,"referenced_works":["https://openalex.org/W131156078","https://openalex.org/W1878977793","https://openalex.org/W1964511936","https://openalex.org/W1975588287","https://openalex.org/W1976567448","https://openalex.org/W1980056453","https://openalex.org/W2000445173","https://openalex.org/W2011966376","https://openalex.org/W2059350047","https://openalex.org/W2066059923","https://openalex.org/W2081276121","https://openalex.org/W2102675827","https://openalex.org/W2104089749","https://openalex.org/W2110641080","https://openalex.org/W2113322194","https://openalex.org/W2114072789","https://openalex.org/W2121051228","https://openalex.org/W2135175231","https://openalex.org/W2153449155","https://openalex.org/W2154407827","https://openalex.org/W2166295381","https://openalex.org/W2188846692","https://openalex.org/W2337454357","https://openalex.org/W2752336761","https://openalex.org/W3122152400","https://openalex.org/W4205288846"],"related_works":["https://openalex.org/W203832111","https://openalex.org/W2027686692","https://openalex.org/W1990285622","https://openalex.org/W7017425138","https://openalex.org/W2097112828","https://openalex.org/W2948928569","https://openalex.org/W2783989626","https://openalex.org/W7217545781","https://openalex.org/W36168761","https://openalex.org/W1972169573"],"abstract_inverted_index":{"STUDY":[0],"OBJECTIVES:":[1],"To":[2],"examine":[3],"glycosylated":[4],"hemoglobin":[5],"(A1C)":[6],"values":[7,26,123,134,194],"longitudinally":[8],"in":[9,19,121,192,249],"patients":[10,23,172,208,221,230,282,309,334],"who":[11,36,81],"newly":[12],"started":[13],"metformin,":[14,210],"sulfonylurea,":[15,211],"or":[16,29,55,179,212],"thiazolidinedione":[17,94,213,244],"monotherapy;":[18],"a":[20,74,232,243,269,336],"subset":[21,307],"of":[22,46,140,171,177,201,217,229,240,251,258,308,328,343],"whose":[24],"A1C":[25,38,50,118,122,133,164,193,203,318,329],"were":[27,60,106,151,160,205,271,292],"7%":[28,57,178],"greater":[30,180],"before":[31,135,181],"starting":[32,182],"therapy":[33,218,259],"(baseline)":[34],"and":[35,93,102,114,132,136,168,189,296],"achieved":[37],"goal":[39,330],"(A1C":[40],"<":[41],"7%)":[42],"during":[43,58,127],"therapy,":[44,96],"rates":[45,291],"secondary":[47,287,312],"failure":[48,247,262,290],"(i.e.,":[49],"value":[51,165,176],"returned":[52],"to":[53,238,260,285,339],">":[54],"=":[56],"therapy)":[59],"compared":[61],"for":[62,87,207,294,311],"each":[63],"drug.":[64],"DESIGN:":[65],"Four-year":[66],"retrospective":[67],"analysis.":[68],"DATA":[69],"SOURCE:":[70],"Administrative":[71],"database":[72],"from":[73,255],"large":[75],"health":[76],"care":[77],"plan.":[78],"PATIENTS:":[79],"Patients":[80,267],"filled":[82],"at":[83],"least":[84],"one":[85,322],"prescription":[86],"metformin":[88,223,284,297],"(5453":[89],"patients),":[90],"sulfonylurea":[91,233,270],"(2373),":[92],"(1590)":[95],"respectively,":[97],"between":[98],"January":[99],"1,":[100],"2001,":[101],"March":[103],"31,":[104],"2004,":[105],"enrolled.":[107],"MEASUREMENTS":[108],"AND":[109],"MAIN":[110],"RESULTS:":[111],"Patients'":[112],"demographic":[113],"clinical":[115],"characteristics,":[116],"baseline":[117,130,163],"values,":[119,319],"changes":[120],"(last":[124],"available":[125],"result":[126],"follow-up":[128,185],"minus":[129],"value),":[131],"after":[137],"the":[138,146,256,306,341],"addition":[139],"an":[141,174],"antidiabetic":[142],"drug":[143,148],"other":[144],"than":[145,227,281,321],"index":[147],"(therapy":[149],"intensification)":[150],"documented.":[152],"Mean":[153,162,184],"age":[154],"was":[155,166,186,195,225,263],"50.7":[156],"years;":[157],"5027":[158],"(53.4%)":[159],"men.":[161],"8.4%,":[167],"about":[169,264],"70%":[170],"had":[173],"AIC":[175],"therapy.":[183,214],"1.9":[187],"years,":[188],"mean":[190,253],"decrease":[191],"1.47%":[196],"(to":[197],"6.91%).":[198],"The":[199,215],"probabilities":[200],"attaining":[202],"goals":[204],"similar":[206,237,293],"receiving":[209,268,283],"rate":[216],"intensification":[219],"among":[220],"taking":[222,231,242],"(24.7%)":[224],"lower":[226],"that":[228,239],"(30.1%,":[234],"p<0.001)":[235],"but":[236],"those":[241],"(24.6%).":[245],"Secondary":[246],"occurred":[248],"36.3%":[250],"patients;":[252],"time":[254],"start":[257],"its":[261],"1.51":[265],"years.":[266],"1.25":[272],"(95%":[273],"confidence":[274],"interval":[275],"[CI]":[276],"1.05-1.50)":[277],"times":[278],"more":[279,320],"likely":[280],"experience":[286],"failure,":[288,313],"whereas":[289],"thiazolidinediones":[295],"(odds":[298],"ratio":[299],"0.78,":[300],"95%":[301],"CI":[302],"0.62-0.99).":[303],"CONCLUSION:":[304],"In":[305],"assessed":[310],"although":[314],"treatment":[315],"initially":[316],"reduced":[317],"third":[323],"experienced":[324],"failure.":[325],"Real-world":[326],"studies":[327],"attainment":[331],"must":[332],"follow":[333],"on":[335],"long-term":[337],"basis":[338],"assess":[340],"maintenance":[342],"glycemic":[344],"control":[345],"over":[346],"time.":[347]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W2169715407","counts_by_year":[{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":2},{"year":2022,"cited_by_count":3},{"year":2021,"cited_by_count":3},{"year":2020,"cited_by_count":3},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":5},{"year":2017,"cited_by_count":4},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":8},{"year":2014,"cited_by_count":9},{"year":2013,"cited_by_count":3},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-20T13:11:24.684918","created_date":"2016-06-24T00:00:00"}
